BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24992174)

  • 21. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
    Ballester LY; Loghavi S; Kanagal-Shamanna R; Barkoh BA; Lin P; Medeiros LJ; Luthra R; Patel KP
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):395-403.e1. PubMed ID: 27268124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].
    Nawata R; Sugiyama A; Harada K; Shinohara K; Yujiri T
    Rinsho Ketsueki; 2019; 60(8):903-909. PubMed ID: 31484887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
    Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies.
    Bagratuni T; Markou A; Patseas D; Mavrianou-Koutsoukou N; Aktypi F; Liacos CI; Sklirou AD; Theodorakakou F; Ntanasis-Stathopoulos I; Gavriatopoulou M; Trougakos IP; Lianidou E; Terpos E; Kastritis E; Dimopoulos MA
    Blood Adv; 2022 Jan; 6(1):189-199. PubMed ID: 34788399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
    Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
    Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
    J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
    King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
    Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.
    Petrikkos L; Kyrtsonis MC; Roumelioti M; Georgiou G; Efthymiou A; Tzenou T; Panayiotidis P
    Biomed Res Int; 2014; 2014():809103. PubMed ID: 25197661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
    Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
    Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
    Bagratuni T; Ntanasis-Stathopoulos I; Gavriatopoulou M; Mavrianou-Koutsoukou N; Liacos C; Patseas D; Kanellias N; Migkou M; Ziogas DC; Eleutherakis-Papaiakovou E; Roussou M; Fotiou D; Terpos E; Kastritis E; Dimopoulos MA
    Leukemia; 2018 Dec; 32(12):2617-2625. PubMed ID: 30026568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
    Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
    Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
    Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
    Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
    Schmidt K; Sack U; Graf R; Winkler W; Popp O; Mertins P; Sommermann T; Kocks C; Rajewsky K
    Front Immunol; 2020; 11():602868. PubMed ID: 33343574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significances of MYD88
    Meng Q; Cao XX; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The MYD88
    Kapoor P
    Br J Haematol; 2019 Nov; 187(4):413-415. PubMed ID: 31298748
    [No Abstract]   [Full Text] [Related]  

  • 40. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
    Drandi D; Ferrante M; Borriero M; Ferrero S
    Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.